Events
| 2009-06-12 |
GenPhar to present at the International Society for Cell and Gene Therapy Conference in Cork, Ireland |
| 2nd-4th September, 2009 Cork, Ireland Dr. John Dong - keynote speaker |
Cancer-targeted gene therapy and cell therapy. Invited speakers include ISCGT executive council members Steve Russell (Director, Molecular Medicine, Mayo Clinic), Al Deisseroth (President, Sidney Kimmel Cancer Center), Karin Gaensler (Professor, Hematology/Oncology, UCSF), Malcolm Brenner (Director, Cell & Gene Therapy Institute, Baylor College of Medicine), David Curiel (Director, Gene Therapy Center, UAB), Savio Woo (Chair, Gene Therapy, Mt. Sinai), Len Seymour (President, British Society of Gene Therapy & Professor, Molecular Pharmacology, Oxford University), Nagy Habib (Pro-Rector and Chair of Surgery, Imperial College London), David Klatzmann (Director, Biotherapeutics Institute, Pierre et Marie Curie University, Paris), Farzin Farzaneh (Chair, Molecular Hematology, Kings College London) and current ISCGT President Noriyuki Kasahara (Director, CURE Vector Core & JCCC Vector Shared Resource Facility, UCLA). Conference website |
| About GenPhar, Inc. GenPhar, Inc. is a biopharmaceutical company dedicated to becoming a leader in developing and producing prophylactic and therapeutic vaccines to protect against the world’s most dangerous diseases. To reach its goals, GenPhar will leverage the advantage of its proven safe and effective ProVax and TheraVax vaccine platforms -- unique technology capable of producing multiple vaccine products. GenPhar's products are divided into two main areas: vaccines for biodefense and vaccines for chronic infectious diseases (including HIV, hepatitis B and hepatitis C). These products will have a large scale socio-economic impact and transformative effect on current research and treatments. GenPhar was founded in 1999 and is headquartered in Mount Pleasant, South Carolina. To learn more about GenPhar and its vaccine programs, please contact us. |
print this page
contact us
site map